Epidemiology of candidemia in Qatar, the Middle East: Performance of MALDI-TOF MS for the identification of Candida species, species distribution, outcome, and susceptibility pattern

Infection

Volumn 42, Issue 2, 2014, Pages 393-404

  Taj Aldeen, S J ^a   Kolecka, A ^b   Boesten, R ^b   Alolaqi, A ^a   Almaslamani, M ^a,c   Chandra, P ^a   Meis, J F ^d,e   Boekhout, T ^b,f,g,h  

^a HAMAD MEDICAL CORPORATION   (Qatar)

^b CBS KNAW FUNGAL BIODIVERSITY CENTRE   (Netherlands)

^c WEILL CORNELL MEDICAL COLLEGE   (Qatar)

^d CANISIUS WILHELMINA HOSPITAL   (Netherlands)

^e RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^f UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^g SECOND MILITARY MEDICAL UNIVERSITY   (China)

^h INSTITUTE OF MICROBIOLOGY   (China)

Author keywords

Antifungal susceptibility; Bloodstream infections; Candidemia; Epidemiology; MALDI TOF MS; Middle East; Outcome; Risk factors

Indexed keywords

ALCOHOL; AMPHOTERICIN B; ANIDULAFUNGIN; CASPOFUNGIN; FLUCONAZOLE; ISAVUCONAZOLE; ITRACONAZOLE; POSACONAZOLE; RIBOSOME DNA; VORICONAZOLE; ANTIFUNGAL AGENT; SPACER DNA;

ADULT; AGED; ANTIFUNGAL ACTIVITY; ARTICLE; BROTH DILUTION; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA ORTHOPSILOSIS; CANDIDEMIA; CONTROLLED STUDY; DISEASE PREDISPOSITION; FUNGUS ISOLATION; GENE IDENTIFICATION; HUMAN; IN VITRO STUDY; MAJOR CLINICAL STUDY; MALE; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MINIMUM INHIBITORY CONCENTRATION; MORTALITY; NONHUMAN; QATAR; RETROSPECTIVE STUDY; RISK FACTOR; SEQUENCE ANALYSIS; SPECIES DISTRIBUTION; TERTIARY CARE CENTER; YEAST; ADOLESCENT; AGE; ANTIFUNGAL RESISTANCE; BLOOD; CANDIDA; CHILD; CLASSIFICATION; DRUG EFFECTS; EPIDEMIOLOGY; EVALUATION STUDY; FEMALE; GENETICS; INFANT; ISOLATION AND PURIFICATION; MASS SPECTROMETRY; METABOLISM; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MIDDLE AGED; PHYSIOLOGY; PRESCHOOL CHILD; SPECIES DIFFERENCE; YOUNG ADULT;

ADOLESCENT; ADULT; AGE FACTORS; ANTIFUNGAL AGENTS; CANDIDA; CANDIDEMIA; CHILD; CHILD, PRESCHOOL; DNA, INTERGENIC; DNA, RIBOSOMAL; DRUG RESISTANCE, FUNGAL; FEMALE; HUMANS; INFANT; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; QATAR; RETROSPECTIVE STUDIES; RISK FACTORS; SPECIES SPECIFICITY; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; YOUNG ADULT;

EID: 84897561300     PISSN: 03008126     EISSN: 14390973     Source Type: Journal    
DOI: 10.1007/s15010-013-0570-4     Document Type: Article

References (40)

1. Colombo AL, Guimarães T, Silva LR, de Almeida Monfardini LP, Cunha AK, Rady P, Alves T, Rosas RC. Prospective observational study of candidemia in São Paulo, Brazil: incidence rate, epidemiology, and predictors of mortality. Infect Control Hosp Epidemiol. 2007;28:570-6.
2. Morgan J. Global trends in candidemia: review of reports from 1995-2005. Curr Infect Dis Rep. 2005;7:429-39. (Pubitemid 41671586)
3. Arendrup MC. Epidemiology of invasive candidiasis. Curr Opin Crit Care. 2010;16:445-52.
4. Sipsas NV, Lewis RE, Tarrand J, Hachem R, Rolston KV, Raad II, Kontoyiannis DP. Candidemia in patients with hematologic malignancies in the era of new antifungal agents (2001-2007): stable incidence but changing epidemiology of a still frequently lethal infection. Cancer. 2009;115:4745-52.
5. Zirkel J, Klinker H, Kuhn A, Abele-Horn M, Tappe D, Turnwald D, Einsele H, Heinz WJ. Epidemiology of Candida blood stream infections in patients with hematological malignancies or solid tumors. Med Mycol. 2012;50:50-5.
6. Sampaio Camargo TZ, Marra AR, Silva CV, Cardoso MF, Martino MD, Camargo LF, Correa L. Secular trends of candidemia in a tertiary care hospital. Am J Infect Control. 2010;38:546-51.
7. Das I, Nightingale P, Patel M, Jumaa P. Epidemiology, clinical characteristics, and outcome of candidemia: experience in a tertiary referral center in the UK. Int J Infect Dis. 2011;15:e759-63.
8. Chalmers C, Gaur S, Chew J, Wright T, Kumar A, Mathur S, Wan WY, Gould IM, Leanord A, Bal AM. Epidemiology and management of candidaemia - a retrospective, multicentre study in five hospitals in the UK. Mycoses. 2011;54:e795-800.
9. Horn DL, Neofytos D, Anaissie EJ, Fishman JA, Steinbach WJ, Olyaei AJ, Marr KA, Pfaller MA, Chang CH, Webster KM. Epidemiology and outcomes of candidemia in 2019 patients: data from the prospective antifungal therapy alliance registry. Clin Infect Dis. 2009;48:1695-703.
10. Chitasombat MN, Kofteridis DP, Jiang Y, Tarrand J, Lewis RE, kontoyiannis DP. Rare opportunistic (non-Candida, non-Cryptococcus) yeast bloodstream infections in patients with cancer. J Infect. 2012;64:68-75.
11. Mokaddas EM, Ramadan SA, Abo el Maaty SH, Sanyal SC. Candidemia in pediatric surgery patients. J Chemother. 2000;12:332-8. (Pubitemid 30640387)
12. Al-Tawfiq JA. Distribution and epidemiology of Candida species causing fungemia at a Saudi Arabian hospital, 1996-2004. Int J Infect Dis. 2007;11:239-44. (Pubitemid 46629036)
13. De Pauw B, Walsh TJ, Donnelly JP, Stevens DA, Edwards JE, Calandra T, Pappas PG, Maertens J, Lortholary O, Kauffman CA, Denning DW, Patterson TF, Maschmeyer G, Bille J, Dismukes WE, Herbrecht R, Hope WW, Kibbler CC, Kullberg BJ, Marr KA, Muñoz P, Odds FC, Perfect JR, Restrepo A, Ruhnke M, Segal BH, Sobel JD, Sorrell TC, Viscoli C, Wingard JR, Zaoutis T, Bennett JE; European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group; National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis. 2008;46:1813-21.
14. Okoli I, Oyeka CA, Kwon-Chung KJ, Theelen B, Robert V, Groenewald JZ, McFadden DC, Casadevall A, Boekhout T. Cryptotrichosporon anacardii gen. nov., sp. nov., a new trichosporonoid capsulate basidiomycetous yeast from Nigeria that is able to form melanin on niger seed agar. FEMS Yeast Res. 2007;7:339-50.
15. Clinical and Laboratory Standards Institute (CLSI). Reference method for broth dilution antifungal susceptibility testing of yeasts; Approved standard - Third edition. CLSI document M27-A3. Wayne: CLSI; 2008.
16. Clinical Laboratory Standards Institute (CLSI). Reference method for broth dilution antifungal susceptibility testing of yeasts; Fourth informational supplement. CLSI document M27-S4. Wayne: CLSI; 2012.
17. Pfaller MA, Andes D, Arendrup MC, Diekema DJ, Espinel-Ingroff A, Alexander BD, Brown SD, Chaturvedi V, Fowler CL, Ghannoum MA, Johnson EM, Knapp CC, Motyl MR, Ostrosky-Zeichner L, Walsh TJ. Clinical breakpoints for voriconazole and Candida spp. revisited: review of microbiologic, molecular, pharmacodynamic, and clinical data as they pertain to the development of species-specific interpretive criteria. Diag Microbiol Infect Dis. 2011;70:330-43.
18. Diekema DJ, Messer SA, Boyken LB, Hollis RJ, Kroeger J, Tendolkar S, Pfaller MA. In vitro activity of seven systemically active antifungal agents against a large global collection of rare Candida species as determined by CLSI broth microdilution methods. J Clin Microbiol. 2009;47:3170-7.
19. Ellis M, Hedstrom U, Jumaa P, Bener A. Epidemiology, presentation, management and outcome of candidemia in a tertiary care teaching hospital in the United Arab Emirates, 1995-2001. Med Mycol. 2003;41:521-8. (Pubitemid 38075566)
20. Clark TA, Slavinski SA, Morgan J, Lott T, Arthington-Skaggs BA, Brandt ME, Webb RM, Currier M, Flowers RH, Fridkin SK, Hajjeh RA. Epidemiologic and molecular characterization of an outbreak of Candida parapsilosis bloodstream infections in a community hospital. J Clin Microbiol. 2004;42:4468-72. (Pubitemid 39362357)
21. Ortega M, Marco F, Soriano A, Almela M, Martínez JA, López J, Pitart C, Mensa J. Candida species bloodstream infection: epidemiology and outcome in a single institution from 1991 to 2008. J Hosp Infect. 2011;77:157-61.
22. Bassetti M, Taramasso L, Nicco E, Molinari MP, Mussap M, Viscoli C. Epidemiology, species distribution, antifungal susceptibility and outcome of nosocomial candidemia in a tertiary care hospital in Italy. PLoS One. 2011;6:e24198. doi:10.1371/journal.pone.0024198.
23. Tortorano AM, Prigitano A, Lazzarini C, Passera M, Deiana ML, Cavinato S, De Luca C, Grancini A, Lo Cascio G, Ossi C, Sala E, Montagna MT. A 1-year prospective survey of candidemia in Italy and changing epidemiology over one decade. Infection. 2013;41:655-62.
24. Pfaller M, Neofytos D, Diekema D, Azie N, Meier-Kriesche HU, Quan SP, Horn D. Epidemiology and outcomes of candidemia in 3648 patients: data from the prospective antifungal therapy (PATH Alliance®) registry, 2004-2008. Diag Microbiol Infect Dis. 2012;74:323-31.
25. Trick WE, Fridkin SK, Edwards JR, Hajjeh RA, Gaynes RP; National Nosocomial Infections Surveillance System Hospitals. Secular trend of hospital-acquired candidemia among intensive care unit patients in the United States during 1989-1999. Clin Infect Dis. 2002;35:627-30.
26. Malani A, Hmoud J, Chiu L, Carver PL, Bielaczyc A, Kauffman CA. Candida glabrata fungemia: experience in a tertiary care center. Clin Infect Dis. 2005;41:975-81. (Pubitemid 41368219)
27. Pemán J, Cantón E, Quindós G, Eraso E, Alcoba J, Guinea J, Merino P, Ruiz-Pérez-de-Pipaon MT, Pérez-del-Molino L, Linares-Sicilia MJ, Marco F, García J, Roselló EM, Gómez-G-de-la-Pedrosa E, Borrell N, Porras A, Yagüe G; FUNGEMYCA Study Group. Epidemiology, species distribution and in vitro antifungal susceptibility of fungaemia in a Spanish multicentre prospective survey. J Antimicrob Chemother. 2012;67:1181-7.
28. Zhang XB, Yu SJ, Yu JX, Gong YL, Feng W, Sun FJ. Retrospective analysis of epidemiology and prognostic factors for candidemia at a hospital in China, 2000-2009. Jpn J Infect Dis. 2012;65:510-5.
29. Boonyasiri A, Jearanaisilavong J, Assanasen S. Candidemia in Siriraj hospital: epidemiology and factors associated with mortality. J Med Assoc Thai. 2013;96:S91-7.
30. Chen PY, Chuang YC, Wang JT, Sheng WH, Yu CJ, Chu CC, Hsueh PR, Chang SC, Chen YC. Comparison of epidemiology and treatment outcome of patients with candidemia at a teaching hospital in Northern Taiwan, in 2002 and 2010. J Microbiol Immunol Infect. 2012;. doi:10.1016/j.jmii.2012.08.025.
31. Kothari A, Sagar V. Epidemiology of Candida bloodstream infections in a tertiary care institute in India. Indian J Med Microbiol. 2009;27:171-2.
32. Lagrou K, Verhaegen J, Peetermans WE, De Rijdt T, Maertens J, Van Wijngaerden E. Fungemia at a tertiary care hospital: incidence, therapy, and distribution and antifungal susceptibility of causative species. Eur J Clin Microbiol Infect Dis. 2007;26:541-7. (Pubitemid 47106810)
33. Ge YP, Boekhout T, Zhan P, Lu GX, Shen YN, Li M, Shao HF, Liu WD. Characterization of the Candida parapsilosis complex in East China: species distribution differs among cities. Med Mycol. 2012;50:56-66.
34. da Silva Ruiz L, Khouri S, Hahn RC, da Silva EG, de Oliveira VK, Gandra RF, Paula CR. Candidemia by species of the Candida parapsilosis complex in children's hospital: prevalence, biofilm production and antifungal susceptibility. Mycopathologia. 2013;175:231-9.
35. Messer SA, Moet GJ, Kirby JT, Jones RN. Activity of contemporary antifungal agents, including the novel echinocandin anidulafungin, tested against Candida spp., Cryptococcus spp., and Aspergillus spp.: report from the SENTRY Antimicrobial Surveillance Program (2006 to 2007). J Clin Microbiol. 2009;47:1942-6.
36. Espinel-Ingroff A, Arendrup MC, Pfaller MA, Bonfietti LX, Bustamante B, Canton E, Chryssanthou E, Cuenca-Estrella M, Dannaoui E, Fothergill A, Fuller J, Gaustad P, Gonzalez GM, Guarro J, Lass-Flörl C, Lockhart SR, Meis JF, Moore CB, Ostrosky-Zeichner L, Pelaez T, Pukinskas SR, St-Germain G, Szeszs MW, Turnidge J. Interlaboratory variability of caspofungin MICs for Candida spp. using CLSI and EUCAST methods: should the clinical laboratory be testing this agent? Antimicrob Agents Chemother. 2013;57:5836-42. doi:10.1128/AAC.01519-13.
37. Spanu T, Posteraro B, Fiori B, D'Inzeo T, Campoli S, Ruggeri A, Tumbarello M, Canu G, Trecarichi EM, Parisi G, Tronci M, Sanguinetti M, Fadda G. Direct MALDI-TOF mass spectrometry assay of blood culture broths for rapid identification of Candida species causing bloodstream infections: an observational study in two large microbiology laboratories. J Clin Microbiol. 2012;50:176-9.
38. Pinto A, Halliday C, Zahra M, van Hal S, Olma T, Maszewska K, Iredell JR, Meyer W, Chen SC. Matrix-assisted laser desorption ionization-time of flight mass spectrometry identification of yeasts is contingent on robust reference spectra. PLoS One. 2011;6:e25712. doi:10.1371/journal.Pone.0025712.
39. Iriart X, Lavergne RA, Fillaux J, Valentin A, Magnaval JF, Berry A, Cassaing S. Routine identification of medical fungi by the new Vitek MS matrix-assisted laser desorption ionization-time of flight system with a new time-effective strategy. J Clin Microbiol. 2012;50:2107-10.
40. Kurzmann CP, Fell JW, Boekhout T. The yeasts: a taxonomic study. 5th ed. Amsterdam: Elsevier; 2011.